In October we added four new startups to the Access EIS portfolio, investing alongside super angels in each case (for more on our super angels, and our co-investment model, see our dedicated page. You can read about our new portfolio companies below.
If you're interested in making an investment and building your own portfolio of promising startups, you can read more about how to get started on our dedicated page, or if you'd prefer to speak to our team about the benefits, angel co-investors, tax reliefs and potential for returns, you can use this link to schedule a call.
Collider
Collider develops and sells non-alcoholic beer infused with adaptogens, nootropics and functional mushrooms, to provide a mood-boosting alternative to alcohol. Its beer is made using traditional ingredients and brewed in exactly the same way as alcoholic beer, but uses special strains of yeast and environmental control to ensure its alcohol content never goes above 0.5%. It's then infused with adaptopgens using a technique that ensures the flavour isn't impacted.
Collider secured a raise of £720k in pre-seed funding in October, exceeding its target of 600k. It has seen very encouraging early sales, selling out six months' worth of product in just two months.
Our angel partner in the round has a CAGR of 58% and their previous investments include Modulr, Qubit, and Brompton Bicycles .
Total Round: £720,000.
Stage Pre-revenue.
CLIQ
CLIQ is a social networking platform that connects communities online and offline, with a mission to address social isolation and allow people to easily form meaningful connections. CLIQ allows users to interact and connect with like-minded individuals and join interest-based clubs and in-person communities.
Our angel partner in the round has an IRR of 25% and their previous investments include Playfind, Bloss and Open for Vintage.
Total Round: £500,000.
Stage Post-revenue.
Batch LDN
Batch LDN designs a range of casual suits and aims to limit industrial fashion waste with a made-to-order production model for its batches. Part of its mission is to raise the standard of sustainability in the fashion industry, and to this end it does not hold stock, and makes each high quality piece by hand, to order, over 4-8 weeks, emphasising slow fashion to limit waste and keep prices down. This model, according to Batch, enables it to produce Savile Row quality suits at 50% of the price.
Our angel partner in the round has an IRR of 31% and their previous investments include VineHealth, AeroCloud Systems and Concr.
Total Round: £650,000.
Stage Post-revenue.
REOME
REOME supplies a range of skincare products that harness the power of advanced biotechnology and biofermentation, representing a new revolution in science-led skincare. Biotechnology has been shown to offer a level of visible results never before seen in skincare products. The ingredients cultuaved through biotechnology have a molecular structure similar to the skin itself, which allows for more skin compatibility, greater absorption, and better results.
Founded by multi-award-winning beauty journalist and brand consultant Joanna Ellner, REOME's approach engages the latest biotechnology processes to creative products that place efficacy at the heart of the brand and actively boost skin health, restore hydration and enhance radiance.
Our angel partner in the round has a CAGR of 29% and their previous investments include Floom, Fabacus and Yaqrit.
Total Round: £1,100,000.
Stage Pre-revenue.
What is Access EIS?
Read our fund brochure for everything you need to know about Access, from the specifics of our innovative co-investment model to our fees, and how to invest.
Register to learn
more about our data,
fund and venture capital